Kura Oncology officer proposes $66.8K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kura Oncology, Inc. (KURA) officer Teresa Bair gave notice of a proposed sale of 8,601 common shares, with an approximate sale date of November 16, 2026 and an aggregate market value of $66,829.77. She acquired the shares from the issuer on November 13, 2026 as a PSU. The past-three-month sales table lists 8,442 performance-based restricted stock units sold September 28 in a sell-to-cover transaction for $88,618.21 in gross proceeds, and 31,487 restricted stock units in an August 19 entry labeled 10b5-1 Sales, with $397,829.73 in gross proceeds.
Key Figures
Key Terms
sell-to-cover financial
Performance-Based Restricted Stock Units financial
10b5-1 Sales regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What past-three-month KURA sales did Teresa Bair report?
AI-generated analysis. How Rhea-AI works. Not financial advice.